Updated odronextamab data from relapsed/refractory diffuse large b-cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long-term outcomes

Phase 2 primary analysis results presented in ash oral session demonstrated a 52% objective response rate (orr), with 31% achieving a complete response (cr)

REGN Ratings Summary

REGN Quant Ranking